Hiv-1 Control after Transient Antiretroviral Treatment Initiated in Primary Infection: Role of Patient Characteristics and Effect of Therapy

Citations Over TimeTop 10% of 2012 papers

Abstract

Background The occurrence of viral control after interruption of an antiretroviral treatment (ART) initiated during primary HIV-1 infection (PHI) is rare and the frequency and predictive factors of such a control are unknown. Methods Within the French ANRS PRIMO Cohort, 164 patients interrupted ART initiated during PHI. We compared patients whose viral load (VL) remained undetectable (<50 copies/ml) or low (50–500 copies/ml) 1 year after ART interruption to those who evidenced a rapid viral rebound. Results After ART interruption, VL remained undetectable for a median time of 4.5 years in 14 patients (‘post-ART controllers') and low in another 14 patients for a median time of 1.5 years. Post-ART controllers also maintained higher CD4 + T-cell counts compared to other patients. Female gender, a high CD4 + T-cell count and low VL during PHI, and a high CD4 + T-cell count and low HIV DNA levels at interruption, were associated with post-ART HIV control. Treatment characteristics did not differ between controllers and non-controllers. Post-ART controllers had lower specific CD8 + T-cell frequencies and CD8 + T-cell activation on ART and after ART interruption than non-controllers. Conclusions Few patients maintain very low VL after interruption of treatment initiated during PHI. Early patient characteristics were the main factors of viral control, although early initiation of ART and the effect of ART on reservoir might contribute to control.

Related Papers

• → The Relation Between Symptoms, Viral Load, and Viral Load Set Point in Primary HIV Infection(2007)88 cited
• → Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?(2002)42 cited
• → Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection(1998)21 cited
• → Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients(2017)6 cited
• → Near point-of-care HIV viral load testing: Uptake and utilization in suburban Yangon, Myanmar(2022)